1800 244 735

Dimebon: disappointing in Alzheimer’s but might work in HD

Dimebon, a drug developed in Russia as an anti-allergy medication, is under investigation as a possible treatment to improve thinking problems in HD. There was disappointment when a recent large trial of Dimebon to treat Alzheimer’s disease in the USA showed no benefit, but hope remains in HD where the DIMOND trial is continuing across Europe.

What is Dimebon?

Dimebon, also known as latrepirdine, is currently being tested for its potential benefit to HD patients. The drug has a unique history – first used in Russia as an antihistamine to treat allergies, scientists looking for Alzheimer’s disease treatments found that it had positive effects in cell and animal models.

Initial success in Alzheimer’s

Based on these lab results, a small ‘open label’ trial was run in Russia with 14 Alzheimer’s disease patients, who showed improvements in their symptoms when treated with Dimebon. An open label trial is one in which both the physicians and patients know that they are being treated with the drug. Open label trials are susceptible to bias through the placebo effect, which causes people to feel better even if they’re taking a pill that doesn’t work.

In light of the positive results in that small open label trial, a larger number of Alzheimer’s disease patients were recruited in Russia for placebo-controlled, double blind trial, where some people participating receive placebo (pills with no drug), while others receive the drug. Neither the doctors nor patients know who is receiving placebo or drug. Such trials are more robust for finding out whether a drug works.

That trial found strong beneficial effects of Dimebon on cognition, behaviour and daily function in Alzheimer’s disease. The magnitude of the benefit was surprising, compared with available Alzheimer’s disease drugs, and led to great excitement in the field.

Dimebon in HD: the DIMOND and HORIZON trials

Because Alzheimer’s disease and Huntington disease have some common features, studies were initiated to investigate whether Dimebon might be beneficial for HD patients. First, a three-month trial (DIMOND) was run to investigate whether Dimebon was tolerated by HD patients. This trial showed that Dimebon was safe, and suggested that treatment lead to improvements in mental performance.

These positive results lead to a larger, longer, trial known as HORIZON. Longer trials of this type are known as ‘Phase III’ trials, and are needed to get regulatory approval to sell any new drug. The HORIZON trial is still underway.

Major Alzheimer’s trial brings disappointment

In the meantime, a major phase III trial for Dimebon in Alzheimer’s disease has been completed in North America, Europe and South America. This trial involved nearly 600 patients and lasted 6 months. In contrast to the earlier studies, this trial showed absolutely no benefit of Dimebon treatment. The reasons for the discrepancy between the trials are a mystery. We don’t know why the phase III trial failed, although failure at this stage is very common. Unfortunately it’s also common to see contradictory results between phase II and III trials.

Despite the disappointing results from the Alzheimer’s disease trial, the reasons for doing the HORIZON trial remain. The positive results in DIMOND suggest that Dimebon might relieve some of the thinking (cognitive) difficulties associated with HD. Currently, treatments are available for the movement symptoms of HD, but no drug is approved to help with the devastating cognitive symptoms experienced by patients. Hopefully, the rapid completion of the HORIZON trial will answer this question for the HD community.

Latest Research Articles

Two birds, one stone: HTT-lowering drugs also target CAG expansions

Published date: 21 May, 2024

Huntingtin (HTT)-lowering and somatic expansion have been two of the hottest topics in Huntington’s disease (HD) research in the past decade. Recent work from a team at Massachusetts General Hospital detailed a serendipitous overlap between the two – certain HTT-lowering drugs can also help regulate the ongoing CAG repeat expansion. Seemingly, this could allow researchers ... Read more

Hats off to brain donors on Brain Donation Awareness Day

Published date: 7 May, 2024

If you’re a frequent reader of HDBuzz, you may have noticed that our articles increasingly thank Huntington’s disease (HD) families for their generous and selfless brain donations. That’s because more and more research is making use of human brains, leading to a better understanding of HD in people. All of that is only possible because ... Read more

A sprinkling of good news for the treatment of HD chorea

Published date: 3 May, 2024

We wrote in August of 2023 about the US approval of a new drug to treat chorea, the movement symptoms of HD. That drug, valbenazine, commercially known as INGREZZA, has just been approved in a new format, one that can be added to soft foods. This news deserves a brief HDBuzz mention. Chorea control Valbenazine ... Read more

A new era for HDBuzz

Published date: 1 May, 2024

HDBuzz strives to be an honest and neutral source of information that Huntington’s disease (HD) families can turn to for trusted, unbiased reporting on research and clinical trial news. We’re honored to have become a global resource for the HD community over the years (14!) and we look forward to building upon the original mission ... Read more

How many is too many? Exploring the toxic CAG threshold in the Huntington’s disease brain

Published date: 21 April, 2024

Drug hunters have been particularly interested in the repeating C-A-G letters of genetic code that lead to Huntington’s disease (HD). The number of CAG repeats gets bigger in vulnerable brain cells over time and may hold the key for slowing or stopping HD. Many scientists have been asking what happens to HD symptoms if we ... Read more

Cry your eyes out: detecting huntingtin in tears

Published date: 10 April, 2024

A recently published collaboration between academic researchers and pharmaceutical companies was successful at detecting huntingtin in tears. The scientists were looking for a new, easy way to track Huntington’s disease (HD). If you don’t mind shedding a tear or two, they found it! Biomarkers – biological metrics in tune with disease progression Tracking disease progression ... Read more